Recombinant human erythropoietin improves neurological outcomes in very preterm infants

OBJECTIVE: To evaluate the efficacy and safety of repeated low‐dose human recombinant erythropoietin (rhEPO) in the improvement of neurological outcomes in very preterm infants. METHODS: A total of 800 infants of ≤32‐week gestational age who had been in an intensive care unit within 72 hours after b...

Descripción completa

Detalles Bibliográficos
Autores principales: Song, Juan, Sun, Huiqing, Xu, Falin, Kang, Wenqing, Gao, Liang, Guo, Jiajia, Zhang, Yanhua, Xia, Lei, Wang, Xiaoyang, Zhu, Changlian
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2016
Materias:
Research Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5084793/
https://www.ncbi.nlm.nih.gov/pubmed/27130143
http://dx.doi.org/10.1002/ana.24677

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5084793/
https://www.ncbi.nlm.nih.gov/pubmed/27130143
http://dx.doi.org/10.1002/ana.24677

Ejemplares similares